Featured Research

from universities, journals, and other organizations

Biopharmaceutical Infrastructure Key To Lower Drug Development Costs

Date:
October 29, 2007
Source:
National Institute of Standards and Technology (NIST)
Summary:
Improvements to the technology infrastructure for researching and developing new biopharmaceuticals would be expected to save the industry hundreds of millions of dollars annually, according to a new economic study sponsored by NIST.

A new NIST-sponsored study found that the biopharmaceutical industry spend a total of $1,219 million on infrastructure technology?884 million on the R&D technology infrastructure including bioimaging, biomarkers, informatics, and gene expression and $335 million on infrastructure for commercial manufacturing and postmarket surveillance.
Credit: NIST

Improvements to the technology infrastructure for researching and developing new biopharmaceuticals would be expected to save the industry hundreds of millions of dollars annually, according to a new economic study* sponsored by the National Institute of Standards and Technology (NIST).

Prepared by RTI International for NIST, the study‘―s authors found that over the last two decades emphasis in new drug development has shifted from small-molecule chemicals to large-molecule proteins and other biopharmaceuticals such as human insulin, gene therapies and specialized antibiotic treatments. The report notes that the biopharmaceutical industry currently spends about $21 billion annually on research and development and has commercialized over 400 products.

Producing and maintaining the infrastructure that supports R&D, manufacturing and postmarket surveillance, including core data, methods, and standards used to determine the quality and efficacy of biopharmaceuticals, costs the industry a total of $1.2 billion annually, according to the report. The study focused on expenditures for four major categories of technical infrastructure: bioimaging, biomarkers, bioinformatics, and gene expression, as well as expenditures for infrastructure supporting processing and quality control for commercial manufacturing and activities involved with postmarket surveilliance. (See chart.)

According to the study, improvements to this infrastructure, such as better standardization of data collection and analysis, would be expected to save between 25 and 48 percent of R&D expenses for each new biopharmaceutical drug approved by the Food and Drug Administration. Better technical infrastructure is also projected to reduce the average development time per approved drug from 122 months to 98 months, a reduction of 20 percent. The study further estimated that total industry manufacturing costs could be reduced over the four major phases of manufacturing by $1.5 billion or 23 percent.

Data for the study were gathered from individual researchers and organizations including a survey of 44 technical experts whose companies represent 42 percent of the combined annual R&D spending and 49 percent of the combined annual R&D sales in biopharmaceuticals.

The ultimate beneficiaries of an improved biopharmaceutical infrastructure, wrote the study‘―s authors, "are patients who gain access to a broader array of novel therapies where development is supported by an effective technology infrastructure."

The full report, Economic Analysis of the Technology Infrastructure Needs of the U.S. Biopharmaceutical Industry, is available at: http://www.nist.gov/director/prog-ofc/report07-1.pdf.

* RTI International, Economic Analysis of the Technology Infrastructure Needs of the U.S. Biopharmaceutical Industry: Planning Report 07-01, August 2007, 201 pp.


Story Source:

The above story is based on materials provided by National Institute of Standards and Technology (NIST). Note: Materials may be edited for content and length.


Cite This Page:

National Institute of Standards and Technology (NIST). "Biopharmaceutical Infrastructure Key To Lower Drug Development Costs." ScienceDaily. ScienceDaily, 29 October 2007. <www.sciencedaily.com/releases/2007/10/071011164809.htm>.
National Institute of Standards and Technology (NIST). (2007, October 29). Biopharmaceutical Infrastructure Key To Lower Drug Development Costs. ScienceDaily. Retrieved April 23, 2014 from www.sciencedaily.com/releases/2007/10/071011164809.htm
National Institute of Standards and Technology (NIST). "Biopharmaceutical Infrastructure Key To Lower Drug Development Costs." ScienceDaily. www.sciencedaily.com/releases/2007/10/071011164809.htm (accessed April 23, 2014).

Share This



More Matter & Energy News

Wednesday, April 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Is North Korea Planning Nuclear Test #4?

Is North Korea Planning Nuclear Test #4?

Newsy (Apr. 22, 2014) — South Korean officials say North Korea is preparing to conduct another nuclear test, but is Pyongyang just bluffing this time? Video provided by Newsy
Powered by NewsLook.com
China Falls for 4x4s at Beijing Auto Show

China Falls for 4x4s at Beijing Auto Show

AFP (Apr. 22, 2014) — The urban 4x4 is the latest must-have for Chinese drivers, whose conversion to the cult of the SUV is the talking point of this year's Beijing auto show. Duration: 00:40 Video provided by AFP
Powered by NewsLook.com
Lytro Introduces 'Illum,' A Professional Light-Field Camera

Lytro Introduces 'Illum,' A Professional Light-Field Camera

Newsy (Apr. 22, 2014) — The light-field photography engineers at Lytro unveiled their next innovation: a professional DSLR-like camera called "Illum." Video provided by Newsy
Powered by NewsLook.com
3 Reasons Why Harley Davidson Is Selling Tons of Epic Hogs

3 Reasons Why Harley Davidson Is Selling Tons of Epic Hogs

TheStreet (Apr. 22, 2014) — Sales of motorcycles have continued to ride back from the depths of hell known as the Great Recession. Excluding scooters, sales of motorcycles increased 3% in 2013. In units, however, at 465,000 sold last year, the total remained about 50% below the peak hit in 2007. Industry leader Harley Davidson’s shareholders have benefited both by the industry recovery and positive headlines emanating from the company. Belus Capital Advisors CEO Brian Sozzi takes you beyond the headlines of the motorcycle maker. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins